Deflazacort - Drug Monograph | DrugInfoSys ODIS

Primary Characteristics

It is of Synthetic origin and belongs to Corticosteroid.

Molecular Weight: 441.5 · Non-proprietary name: Deflazacort.

Pharmacokinetics

Elimination: plasma half-life is 1.1-1.9, renal excretion is 70%.

Indications

Deflazacort is primarily indicated in conditions like Inflammation, Status epilepticus (unlicensed use).

Contraindications

Deflazacort is contraindicated in conditions like Mild or moderate typhoid due to multiple antibacterial-resistant organisms, Tuberculosis resistant to first line drugs.

Dosage

Deflazacort's dosage details are as follows:

Dose	Single Dose	Frequency	Route
Adult Dosage
120 mg	120 mg	Every 24h	Initial
10.5 mg	10.5 mg	Every 24h	Maintainance
Paediatric Dosage (20kg)
0.2 – 1.5 mg/kg	—	—
Neonatal Dosage (3kg)
No data.

Drug Interactions

17 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Deflazacort in overdosage may give rise to further complications which include Thromboembolism.

Deflazacort is known to cause more or less tolerable side effects which are usually transient. These include Abnormal distension, Acne, Acute pancreatitis, Amenorrhea, Bruising , Candidiasis , Cushing syndrome, Depression, Dyspepsia , Esophageal ulceration, Euphoria, GI disturbance, Glaucoma , Hiccups, Impaired skin, Increased appetite, Insomnia, Malaise, Menstrual irregularity, Musculoskeletal Endocrine, Nausea, Oesteoporosis, Ophthalmic and Electrolyte disturbances, Peptic ulcer, Proximal myopathy, Psychological dependence, Psychosis, Skin Atrophy, Weight gain.

Warnings / Precautions

Deflazacort should be used with caution in patients with adrenal supression and infection (prolong course of corticosteroid increase susceptibility to infection and severity of infection; clinical presentation of infection may also be atypical); children and adolescents (growth retardation possibly irreversible), elderly (close supervision required perticularly on long-term treatment); frequent monitoring required if history of tuberculosis (or X-ray changes), hypertension, recent myocardial infarction (rupture reported), congestive heart failure, liver failure, renal impairment, diabetes mellitus including family history, osteoporosis (post-menopausal women at special risk), glaucoma (including family history), severe effective disorders (perticularly if history of steroid-induced psychosis), epilepsy, peptic ulcer, hypothyroidism, history of steroid myopathy; pregnancy, pregnancy and breast-feeding.

Available Brands

None recorded.

Storage Conditions

Deflazacort should be stored .

Drug Classification

1.25.1.1 — Oral/Parenteral antiasthmatics